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Background: Specific allergen immunotherapy (SIT) is an effective allergy treatment, 
but it is unclear whether SIT is effective for atopic eczema (AE). We undertook a 
systematic review to assess SIT efficacy and safety for treating AE. 
Methods: We searched databases, ongoing clinical trials registers, and conference 
proceedings up to July 2015. Randomised-controlled trials (RCTs) of SIT using 
standardised allergen extracts, compared with placebo/control for treating AE in patients 
with allergic sensitisation were eligible.  
Results: We identified 12 eligible trials with 733 participants. Interventions included 
subcutaneous (6 trials), sublingual (4 trials), oral, or intradermal SIT in children/adults 
allergic to house dust mite (10 trials), grass pollen or other inhalants. Risk of bias was 
moderate, with high loss to follow-up and non-blinding as the main concerns. For our 
primary outcomes three studies (208 participants) reported no significant difference - 
patient-reported global disease severity improvement RR 0.75 (95%CI 0.45, 1.26); 
eczema symptoms mean difference -0.74 on a 20-point scale (95%CI -1.98, 0.50). Two 
studies (85 participants) reported a significant difference - SIT improved global disease 
severity RR 2.85 (95%CI 1.02, 7.96); and itch mean difference -4.20 on a 10-point scale 
(95%CI -3.69, -4.71). Meta-analysis was limited due to extreme statistical heterogeneity. 
For some secondary outcomes, meta-analyses showed benefits for SIT eg investigator-
rated improvement in eczema severity RR 1.48 (95%CI 1.16, 1.88; 6 trials, 262 
participants). We found no evidence of adverse effects. The overall quality of evidence 
was low. 
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Conclusion: We found no consistent evidence that SIT is effective for treating AE, but 
due to the low quality of evidence further research is needed to establish whether SIT 
has a role in AE treatment. 
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Introduction: 
Atopic eczema (AE) affects 15% to 30% of children and 2% to 10% of adults worldwide, 
and has a significant quality of life impact(1,2). AE is associated with allergic 
sensitisation, and can be exacerbated following allergen exposure, suggesting that 
interventions aimed at reducing allergen-specific responses may be effective for AE 
treatment(3). 
There is high level evidence that SIT reduces symptoms in people with allergic rhinitis, 
allergic conjunctivitis, asthma and insect sting allergy(4-8). The evidence for SIT as a 
treatment of AE is less clear(9,10). We undertook a systematic review to evaluate the 
efficacy and safety of SIT for treating AE, by searching the literature systematically and 
analysing all evidence arising from randomised controlled trials. A more detailed version 
of this review will be published and updated in the Cochrane Database of Systematic 
Reviews(11).  
 6 
Methods: 
We conducted systematic searches for all relevant randomised controlled trials (RCTs) 
regardless of language or publication status (published, unpublished, in press, or in 
progress). The plans outlining hypothesis and methods were published as a protocol 
'Specific allergen immunotherapy for the treatment of atopic eczema'(11). 
 
Search Strategy 
We searched the following databases up to July 20, 2015: the Cochrane Skin Group 
Specialised Register, CENTRAL in The Cochrane Library (2014, Issue 8), MEDLINE 
(from 1946), Embase (from 1974), LILACS (from 1982), ISI Web of Science (from 
2005), the GREAT database (Appendix 2).  We searched the following trials registers 
up to August 3, 2015 using the terms 'immunotherapy and (eczema or dermatitis)': 
metaRegister of Controlled Trials, U.S. National Institutes of Health Ongoing Trials 
Register, Australian and New Zealand Clinical Trials Registry, World Health 
Organization International Clinical Trials Registry platform, and Ongoing Skin Trials 
Register. We searched abstracts from recent European Academy of Allergy and Clinical 
Immunology, and the American Academy of Allergy, Asthma and Immunology annual 
meetings from 2010 to 2015. We checked the bibliography of included studies and 
review articles for further references to relevant trials. We contacted the primary author 
of each included study to identify additional published and unpublished studies. We 
contacted allergen immunotherapy product manufacturers to request details of 
published or unpublished studies of SIT which have included eczema as an outcome 
measure. 
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Selection criteria 
We included RCTs studying adults and children with AE and allergic sensitisation to an 
inhalant or food allergen. Allergic sensitisation needed to be proven using an objective 
test such as a positive skin prick test or high circulating levels of allergen-specific IgE 
antibody detected by a specific blood test. Trials focusing on allergic rhinitis or asthma 
without eczema were excluded(12). Where trials included participants with and without 
AE, the trial was only included if the results for the participants with AE were reported 
separately. We included RCTs with intervention using high dose immunotherapy with 
standardised allergen extracts for single or mixed allergens, administered by the 
sublingual, subcutaneous, intradermal, or oral route; compared with placebo or standard 
treatment such as emollients, topical corticosteroids, or topical calcineurin inhibitors. All 
appropriate allergens were considered at all doses and all durations of treatment. We 
were interested in both subjective and objective outcomes. Primary outcomes were: 
participant- or parent-reported global assessment of disease severity at the end of 
treatment, participant- or parent-reported specific symptoms of eczema, and adverse 
events. Secondary outcomes were: investigator- or physician-rated global assessment 
of disease severity at the end of treatment, parent- or participant-rated eczema severity 
assessed using a published scale, investigator-rated eczema severity assessed using a 
published scale, use of other medication for treatment of eczema during the intervention 
period, and validated eczema-related quality of life scores. 
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Selection of studies 
Two authors (RB, and MC or HT) independently checked titles and abstracts identified 
from the searches, looked at the full text of all studies of possible relevance for 
assessment, and decided which trials met the inclusion criteria. Any disagreements 
were resolved by discussion between the authors, and the planned recourse to a third 
author (HN) for arbitration did not prove necessary. Further information was sought from 
trial authors when needed to confirm eligibility. 
 
Data extraction 
Two authors (RB, and HT or LM) independently extracted data from included trials, and 
entered data into a specially designed data extraction sheet, and the authors met to 
compare results. MC, RB, and HT wrote to all authors requesting additional information 
as required. We contacted authors when details about study design or descriptive 
statistics for outcomes were not presented in the paper (i.e. mean, SD). If the authors 
did not respond within a reasonable time (six to eight weeks) to at least two separate 
written requests for information, we conducted the review based on available 
information. 
 
Assessment of risk or bias 
We assessed and documented the risk of bias in the included studies by concentrating 
on the following six parameters to assess quality: random sequence generation, 
allocation concealment, blinding, incomplete outcome data, selective outcome reporting, 
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and other potential sources of bias as specified in the Cochrane Handbook for 
Systematic Reviews of Interventions (19). Three authors (RB, HT, and HN) 
independently assessed risk of bias: we were not masked to study details. We met to 
resolve any disagreements, and the planned recourse to a fourth author (MC) for 
arbitration did not prove necessary. Judgments were reported as ‘low risk’, ‘high risk’, or 
‘unclear risk’. 
 
Measurement of treatment effect 
For continuous data we calculated individual and pooled statistics as mean differences 
(MD) where studies used the same outcome measure, reported with 95% Confidence 
Interval (CI), where possible. For dichotomous outcomes, we expressed results as a 
risk ratio (RR) with 95% CI, where possible. 
 
Subgroup analyses 
We planned 5 a priori subgroup analyses: immunotherapy type (sublingual and 
subcutaneous); allergen type (seasonal inhalant, perennial inhalant, food, microbial); 
age of participants (up to 4 years, 5 to 11, 12 to 17, and 18 or over); immunotherapy 
regimens to be subdivided empirically into low, intermediate, and high dose therapy 
according to content of major allergen per dose; and AE severity at randomisation. 
 
Assessment of heterogeneity 
We tested for heterogeneity using the I² statistic and substantial statistical heterogeneity 
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was defined as I² > 50% (20). Where appropriate, statistical or clinical heterogeneity 
was explored using sensitivity or subgroup analysis. Quantitative analyses of outcomes 
were, wherever possible, on an intention-to-treat basis. We analysed continuous 
outomes using the Mantel-Haenszel method and dicothomous dichotomous outcomes 
using the inverse variance method. We combined appropriate data from individual 
studies in a meta-analysis only where heterogeneity measured by I² < 75%, using a 
random-effects model. Where meta-analyses were not applicable, we reported a 
narrative synthesis of outcomes from relevant studies. We used the GRADE approach 
for assessing overall quality of evidence contributing to each finding(13). 
 
Sensitivity analyses 
Post-hoc sensitivity analyses were not performed due to the small number of studies 
contributing to meta-analyses. 
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Results 
Our search identified 1556 records (see PRISMA flow diagram Figure 1). Ninety-one 
records were selected for full text screening. Reasons for rejecting 69 titles were: review 
article (n=28), not RCT (n=13), not SIT (n=5), not AE (n=12), and no appropriate control 
(n=6). We found one ongoing trial with no outcome data yet available(14). Overall, 26 
reports of 12 separate RCTs with 733 participants met the inclusion criteria(15-26). We 
contacted all authors for original data and clarification of methods, and received further 
details for four trials(15,21,24,26). 
 
Characteristics of included studies (Table 1) 
Studies were conducted in specialist allergy centres in the UK(17,26), Italy(15,16,22), 
the USA(18), Germany(21), Belgium(19), Poland(25), Columbia(24), Mexico(20), and 
China(23). Two studied adults((21,23), six studied children(15-17,20,22,26) and four 
studied both children and adults(18,19,24,25). Ten studies recruited participants 
sensitised to Dermatophagoides pteronyssinus(15-17,19-24,26), one study house dust 
mites or grass pollen(25), and one study included allergic sensitisation to a group of 
unspecified inhalant antigens(18). Six trials used subcutaneous immunotherapy 
(SCIT)(17,18,21,24-26), four sublingual immunotherapy (SLIT)(15,20,22,23), one 
intradermal immunotherapy(19), and one oral immunotherapy(16). Eight trials compared 
intervention with placebo(17-22,25,26) and four with standard treatment(15,16,23,24). 
Treatment duration was under a year in one trial(19) and at least a year in all others(15-
18,20-26). 
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Risk of bias 
Overall the risk of bias was moderate. Risk of performance bias due to non-blinding was 
high in two open-label studies, both of which reported data for our primary outcome 
analyses(15,24). There was high attrition bias in eight studies with high loss to follow up 
(up to 51%) or post-randomisation exclusions(15,17-23). Figure 2 summarises the risk 
of bias for included studies. 
 
Primary Outcomes 
1. Participant- or parent-reported global assessment of disease severity 
Warner(26) found improvement in 7/9 (78%) treated with SIT compared with 3/11 (27%) 
treated with placebo (RR 2.85, 95% CI 1.02 to 7.96; P = 0.04). Glover(17) found 
improvement in 8/13 (62%) treated with SIT compared with 9/11 (81%) treated with 
placebo (RR 0.75, 95% CI 0.45 to 1.26; P = 0.38). Meta-analysis was not performed 
due to high heterogeneity between these two studies (I2=83%). Pajno(22), found no 
significant difference reported as a Visual Analogue Score (VAS) between treatment 
groups but did not report data; and Leroy(19) reported this outcome but not whether 
there was a significant difference between SIT and control groups. Quality of evidence 
was low due to heterogeneity (inconsistency) and imprecision. 
 
2. Participant- or parent-reported specific symptoms of eczema 
Meta-analyses of two trials with 184 participants(15,21) found no significant reduction in 
SCORAD C with SIT (MD -0.74, 95% CI -1.98 to 0.50; I2=0%) or the component parts of 
SCORAD C - severity of sleep disturbance (MD -0.49, 95% CI -1.03 to 0.06; I2=0%) and 
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itch severity (MD -0.24, 95% CI -1.00 to 0.52; I² = 0%). A third, non-blinded study(24) 
found reduced overall symptoms (P < 0.01) and reduced itch severity measured on a 
VAS from 0-10 (MD -4.20, 95% CI -3.69 to -4.71). Meta-analysis of itch severity data 
from the three studies was not undertaken due to extreme heterogeneity (I² = 98%) 
attributable to the non-blinded study(24). Data are summarised in Figure 3. Quality of 
evidence was very low due to study limitations (non-blinding, high loss to follow up), 
imprecision, and heterogeneity. 
 
3. Adverse events 
We found no evidence for adverse effects from trials of SIT used to treat AE. Seven 
trials(15,17,21-25) with 484 participants reported local adverse reactions: 90/280 
(32.1%) participants treated with SIT had a local reaction, compared to 44/204 (34.4 %) 
with no treatment (RR 1.27, 95% CI 0.89 to 1.81; I2=25%; Figure 4). Seven 
trials(15,17,21-25) with 492 participants reported systemic adverse reactions: 18/282 
(6.4%) participants treated with SIT had a systemic reaction, compared to 15/210 
(7.1%) with no treatment (RR 0.78, 95% CI 0.41 to 1.49; I2=0%; Figure 4). Quality of 
evidence was moderate due to imprecision. 
 
Secondary outcomes 
1. Investigator- or physician-rated global assessment of disease severity 
Meta-analysis of six studies(15,16,18,23-25) with 262 participants, found a significant 
improvement in disease severity was more likely after SIT than in controls (RR 1.48, 
95% CI 1.16 to 1.88; I² = 19%; Figure 5). Quality of evidence was very low due to study 
limitations (non-blinding) and imprecision. 
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2. Participant or parent-rated eczema severity assessed using a published scale 
No study reported this outcome other than those reporting SCORAD part C, which we 
included as a primary outcome, eczema symptoms. 
 
3. Investigator-rated eczema severity assessed using a published scale 
Six studies(15,20-24) with 435 participants reported this outcome as total SCORAD. 
Meta-analysis of three trials((15,21,24) with 244 participants, showed significant 
improvement in end of treatment SCORAD (MD -5.79, 95% CI -7.92 to -3.66; I² = 0%; 
Figure 6). Three further studies reported improved SCORAD with SIT. Qin(23) found 
increased participants with SCORAD change > 60% in SIT (77.78%) than control 
(53.85%) (P < 0.05) – we included these data in analysis of investigator- or physician-
reported improvement in global severity (Figure 5). Luna-pech(20) found greater 
reduction in SCORAD with SIT (-18.4 + 6.5) than control (-6.6 + 4.1; P = 0.008). This 
effect was greater for patients with severe eczema at baseline. Pajno(22) reported 
greater SCORAD improvement with SIT than control, in graphical data (P < 0.001) but 
no numerical data were available. Glover and Galli(16,17) reported no significant 
difference using unpublished scales. Quality of evidence was very low due to study 
limitations (non-blinding, high loss to follow up) and imprecision.  
 
4. Use of other medication for treatment of eczema during the intervention period 
Eight studies with 434 participants reported this outcome. Overall 4 studies reported 
reduced medication use with SIT, and 4 studies reported no significant difference. 
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Silny(25) reported no statistically significant difference between treatment groups, in the 
use of topical steroids (RR 1.33, 95% CI 0.74 to 2.41). Glover(17) stated there was no 
significant difference in the use of topical steroids between treatment groups, without 
reporting numerical data. Two studies reported the use of systemic steroids for AE. 
Kaufman(18) found no difference - SIT 8/16 (50%) versus control 4/10 (40%; P = 0.7). 
Sanchez(24) reported less systemic steroid use with SIT 12/29 (41%) versus control 
4/31 (13%; P = 0.02). Meta-analysis was not performed due to high statistical 
heterogeneity (I² = 76%). Novak(21) reported a non-significant 32% difference in the 
median area under the curve for a medication score combining topical and systemic 
medication, (19330 SIT, 28420 control; P = 0.08). Pajno(22) reported a significant 
decrease in frequency (P = 0.03) and days (P = 0.01) of rescue medication use (oral 
hydroxyzine and topical steroids) with SIT. Luna-Pech(20) reported significantly less 
use of rescue medications (not defined) in treatment compared to control but no details 
were provided. Qin(23) reported a lower average daily drug score in treatment (mean 
0.5 SD 0.4) than control (mean 1.3 SD 0.7), (P <0.01). Quality of evidence was low, due 
to study limitations (non-blinding; high loss to follow up) and heterogeneity. 
 
5. Validated eczema-related quality of life scores 
Novak(21) reported a validated eczema-related quality of life score, the Dermatology 
Life Quality Index (DLQI). They found no difference between treatment groups in end of 
treatment score – SIT median 3.0 (IQR 1.0, 8.0), control 3.5 (1.0, 10.5; P = 0.53). 
Subgroup analysis 
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Subgroup analyses failed to identify a type of immunotherapy, type of allergen, 
participant age, dose of allergen, or severity of AE with a different efficacy or safety 
profile, although these analyses were generally inconclusive due to the limited data 
available. For SCIT vs SLIT, no SLIT data was available for the primary outcome 
‘participant- or parent-reported global assessment of severity’; no subgroup difference 
was identified for the primary outcome ‘participant- or parent-reported specific 
symptoms’ or ‘systemic adverse reactions’; and a subgroup difference for the primary 
outcome ‘local adverse reactions’ was identified. We found limited evidence that SLIT is 
associated with increased local adverse reactions compared to SCIT. Two SLIT studies 
with 164 participants showed RR 9.76 (95%CI 1.28, 74.26; I2 = 0%); five SCIT studies 
with 320 participants showed RR 1.18 (95%CI 0.90, 1.55; I2 = 0%) – test for subgroup 
differences P=0.04, I2 = 75%. For type of allergen, data was only available for one 
subgroup ‘perennial allergen’ so no analyses were undertaken. For participant age, data 
was only available for one subgroup ’18 years or over’ so no analyses were undertaken. 
For dose of allergen, no available data were stratified to our planned subgroups so no 
analyses were undertaken. 
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Discussion 
In this systematic review undertaken within the Cochrane Collaboration, we did not find 
evidence that SIT is an effective treatment for AE as judged by our pre-specified 
primary outcomes. The evidence regarding efficacy was marked by inconsistency in 
study findings, and the overall grade of evidence was low. This suggests a need for 
further rigorous, well-powered studies to clarify whether SIT has benefits for people with 
AE.   
Our findings contrast with those of a recent systematic review(9), which reported that 
SIT is effective for treating AE. Odds ratio for improved eczema was 5.35 (95%CI 1.61, 
17.77), however the authors combined very heterogeneous outcomes in meta-analysis 
which may not be appropriate(10), and reported no registered protocol. In another 
recent systematic review(27), methodological flaws in existing evidence were identified, 
and the authors’ conclusions were similar to ours – that rigorous studies are needed. 
The authors identified five of the twelve trials included in our review, and an additional 
two that we excluded because they were not RCTs(28,29). 
Although some studies and meta-analyses in our review reported positive findings, the 
quality of evidence in these analyses was low due to lack of blinding of outcome 
assessment, high post-randomisation losses to follow up, small study size(s) and 
inconsistency of findings (Table 3). Meta-analysis was limited due to heterogenous 
outcome assessments and reporting methods across studies, and confidence intervals 
were often wide with significant statistical heterogeneity. Some positive meta-analyses 
were statistically significant, but may not be clinically significant. For example the finding 
of reduced total SCORAD (Figure 6) was statistically significant, but the 95%CI of this 
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effect (-7.92, -3.66) excluded the minimal clinically important difference for this outcome 
measure which is 8.7 points(30). Several outcomes were based on analysis from the 
trial of Novak(21) with a large number of participants but high loss to follow-up and 
negative findings. Three trials(15,21,24) had more positive findings than the others, 
showing a clear beneficial effect on participant- or parent-reported eczema symptoms 
and investigator- or physician-reported global eczema severity in the form of SCORAD. 
It is not clear why the findings of these trials differed, especially the trial of Sanchez 
which used a similar population, intervention, comparator and outcome to the study of 
Novak. There was however a risk of detection bias due to non-blinding of participants or 
investigators in the studies of Sanchez and Di Rienzo(15,24). 
 
Although AE is associated with allergic sensitization, it is not solely and directly caused 
by IgE-mediated allergic responses. Indeed, recent evidence suggests that some 
allergic sensitization may be a consequence rather than a cause of AE(3,31). The lack 
of proven efficacy in our study may reflect inappropriately targeting allergens 
responsible for sensitization but not clinical relevance. Future trials could consider 
establishing the clinical relevance of sensitisation in study participants, for example 
using response to allergen exposure in an environmental challenge chamber as an 
inclusion criterion (3). Treatments directed at the allergic immune response are effective 
for treating eczema(32), and acute exacerbations of eczema can be precipitated by 
inhalant allergen exposure in sensitized individuals(3). However environmental stimuli 
other than inhalant allergens are important causes of eczema exacerbations(33). 
People with AE often have specific IgE to autoantigens, and high level specific IgE to 
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microbial antigens(31,34). SIT directed to the inhalant allergens used in the included 
studies may therefore not be addressing the most important allergenic triggers in many 
cases. Future trials should consider whether SIT with other allergens may be 
appropriate. 
 
Adverse reaction rates were not significantly increased with immunotherapy in the 
included studies, but evidence from other settings suggests that SIT carries a 
significantly increased risk of severe allergic reactions(4). While this might suggest that 
the allergic sensitisation to the SIT allergens in the trial participants is of little clinical 
relevance, or that the allergen extracts used were of low potency, it may equally reflect 
the small number of trials and participants contributing to the adverse events analysis. 
 
Our ability to explore the dataset for specific groups of patients who might respond 
better to SIT than others was limited. Data were sparse or absent for pre-specified 
subgroup analyses, and we were not able to undertake individual patient data meta-
analysis. Therefore we cannot exclude the possibility that SIT is effective for specific 
subgroups of patients with eczema, and this remains an important area to explore in 
future research studies. 
 
SIT is a well-established treatment with proven efficacy for several allergic diseases. 
Historically some immunotherapy guidelines have included atopic eczema as a relative 
contraindication to using SIT. This is not included in current European or North 
American guidance (35, 36), and we found no evidence to support adverse effects of 
 20 
SIT when used in patients with eczema. 
In conclusion, we found no consistent evidence that SIT provides a treatment benefit for 
people with AE compared with placebo or no treatment,, however the quality of 
evidence was low, and study findings were markedly inconsistent. Therefore positive 
effects for SIT in AE cannot currently be excluded. Further large, rigorously conducted 
randomised controlled trials using modern high quality allergen formulations with a 
proven track record in other allergic conditions, which evaluate patient-reported primary 
outcome measures are needed. Consideration should also be given to the use of non-
conventional allergens in SIT for eczema, which may be more relevant to this disease 
than the classical inhalant allergens. 
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Table 1 Characteristics of Included Studies 
Trial Methods Participants Intervention (n) Comparison (n) Primary Outcome (s) 
reported 
Secondary Outcome (s) 
reported 
Di Rienzo OL, RCT 57 children aged 5-18 years with (+) SPT and (+) RAST to 
DF and/or DP, and (+) atopy patch test to HDM, and AE 
SLIT DF and DP 
(30) 
No SLIT (27) Yes Yes 
Galli RCT 34 children aged 0.5-12 years with (+) SPT and/or (+) RAST 
to DP and AE 
Oral DP (16) No treatment (18) No Yes 
Glover DB, RCT 26 children aged 5-16 years with (+) SPT to DP and severe 
AE 
SCIT DP (13) Placebo (13) Yes Yes 
Kaufman RCT  52 children and adults aged 2-47 years with (+) SPT to mix 
of inhalant allergens, and uncontrolled AE 
SCIT  inhalant 
allergens (25) 
Placebo (27) No Yes 
Leroy RCT 24 children and adults aged 17-64 years with (+) SPT and 
(+) sIgE to DP, and AE resistant to environmental treatment 
Intradermal DP 
(13) 
Placebo (11) Yes Yes 
Luna-Pech DB, RCT 68 children aged 4-10 years with monosensitisation to DP 
and moderate to severe AD 
SLIT DP (34) Placebo (34) No Yes 
Novak DB, RCT 168 adults aged 18-66 with (+) SPT to DP and DF and (+) 
sIgE to DP or DF, and AE 
SCIT DPP (112) Placebo (56) Yes Yes 
Pajno DB, RCT  56 children aged 5-16 years with (+) SPT and (+) RAST to 
HDM, and AE with SCOARD >8 
SLIT DP and DF 
(28) 
Placebo (28) Yes Yes 
Qin ?OL, RCT 107 adults aged 18-46 years with (+) SPT to DF, and 
moderate AE 
SLIT DF (58) Control (49) Yes Yes 
Sanchez OL, RCT 65 children and adults aged 3-25 years with (+) sIgE to DF 
and DP, and AE 
SCIT to DPP (32) Placebo (33) Yes Yes 
Silny  DB, RCT 20 children and adults aged 5-40 years with (+) SPT and (+) 
sIgE to HDM or grass, and AE 
SCIT DP/DF or 
grass (10) 
Placebo (10) Yes Yes 
Warner  TB, RCT 56 children aged 5-14 years with asthma, and AE SCIT DP (28) Placebo (28) Yes No 
AE, atopic eczema; DB, double-blind; DF, Dermatophagoides farinae; DP, Dermatophagoides pteronyssinus; DPP, DePigmented Polymerized extract; HDM, house dust mite; OL, 
open-label; SCIT: subcutaneous immunotherapy; SCORAD, SCORing Atopic Dermatitis; sIgE, specific Immunoglobulin E; SLIT, sublingual immunotherapy; SPT, skin prick test; 
RAST, Radioallergosorbent test; RCT, randomised controlled trial; TB, triple-blind. 
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Table 2 Summary of Findings for specific immunotherapy compared with no immunotherapy for atopic eczema 
Patient or population: adults and children with atopic eczema and inhalant allergen sensitisation 
Settings: specialist allergy centres in UK (2 trials), Italy (3 trials), USA, Germany, Belgium, Poland, Columbia, and China 
Intervention: specific allergen immunotherapy 
Comparison: no immunotherapy 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
 (95% CI) 
Number of 
Participants 
 (studies) 
Quality of the 
evidence 
 (GRADE) 
Comments 
Assumed risk Corresponding risk 
No immunotherapy Specific allergen 
immunotherapy 
Participant- or parent-
reported global 
assessment of 
disease severity 
Follow-up: 6 to 12 
months 
See comments See comments Not 
estimable 
44a 
 (2) 
⊝⊝ 
lowb 
Improvement in: 7/9 (78%) immunotherapy and 
3/11 (27%) placebo; P = 0.04 (Warner) and 
8/13 (62%) immunotherapy and 9/11 (81%) 
placebo; P = 0.38 (Glover); 
Unexplained statistical heterogeneity, data not 
pooled 
Participant- or parent-
reported specific 
symptoms of eczema 
Follow-up: 12 to 18 
months 
 
SCORAD C measured 
as combination of two 
Visual Analog Scale 
(one for itch, one for 
sleep disturbance), 
each on a scale from 0, 
no symptoms, to 10, 
maximum symptoms 
The mean SCORAD C 
score ranged across 
control groups from 
3.07 to 5.29 
 
 
 
The mean SCORAD C 
sleep severity score 
ranged across control 
groups from 
0.8 to 2.31 
(Di Rienzo; Novak) 
The mean SCORAD C 
score in the 
immunotherapy group 
was on average 
0.74 lower 
(95% CI -1.98 to 0.50) 
 
The mean SCORAD C 
sleep severity score in the 
immunotherapy group 
was on average 
0.49 lower 
(95% CI -1.03 to 0.06) 
(Di Rienzo; Novak) 
 339a 
 (6) 
⊝⊝⊝ 
very lowc 
Itch: 
SCORAD C itch severity at the end of treatment: 
MD -0.24, 95% CI -1.00 to 0.52; I² = 0% for (Di 
Rienzo) and (Novak) 
  
Itch severity score: MD -4.20, 95% CI -3.69 to -
4.71 for Sanchez 2012. 
 
Unexplained statistical heterogeneity, data not 
pooled 
 
Adverse events - any 
systemic reaction  
Follow-up: 6 to 18 
months 
Low risk population RR 0.78 
(0.41 to 
1.49) 
492a 
 (7) 
⊝ 
moderated 
 
0 per 1000 0 per 1000 
 (0 to 0) 
Medium risk population 
71 per 1000 55 per 1000 
 (29 to 106) 
High risk population 
163 per 1000 127 per 1000 
 (67 to 243) 
Investigator- or 
physician-rated global 
assessment of 
disease severity 
Follow-up: 1 to 3 years  
Low risk population RR 1.48 
(1.16 to 
1.88) 
 
286a 
 (7) 
⊝⊝⊝ 
very lowe 
 
0 per 1000 0 per 1000 
 (0 to 10) 
Medium risk population 
471 per 1000 697 per 1000 
 (546 to 885) 
High risk population 
778 per 1000 1151 per 1000 
 (903 to 1462) 
Investigator- or The mean SCORAD The mean SCORAD  435a ⊝⊝⊝  
 26 
physician-rated 
eczema severity using 
a published scale 
Follow-up: 12 to 18 
months 
score ranged across 
control groups from 
26.7 to 32.6 
(Di Rienzo; Novak; 
Sanchez) 
score in the 
immunotherapy group 
was on average 
5.79 lower 
(95% CI -7.92 to -3.66) 
(Di Rienzo; Novak; 
Sanchez) 
(6) very lowf 
GRADE: Grading of Recommendations Assessment, Development and Education; CI: Confidence interval; RR: Risk Ratio. 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the 
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Assumed risks are based on the total control group risk across all included studies (medium-risk population) and the included studies with the lowest (low-risk population) and highest 
(high-risk population) control group risks. 
a. The number of total participants did not include those there were lost to follow-up. The number of participants and trials included those that contributed to narrative synthesis. 
b. Reasons for downgrading: unexplained heterogeneity (serious, -1), and imprecision (serious, -1). There was significant heterogeneity (I² = 83%) between the estimate of treatment 
effects in the two studies (Warner and Glover) and data was not pooled. The information size is small. 
c. Reasons for downgrading: study limitations of the study design (serious, -1), imprecision (serious, -1), and unexplained heterogeneity (serious, -1). Two trials were non-blinded. 
Moderate proportions of participants were not analysed (losses to follow up). The information size is small. Most subgroups of estimate of treatment effects were not statistically 
significant with itch displaying high heterogeneity (I² = 98%). Data were not pooled due to different symptoms and different scoring systems reported. 
d. Reason for downgrading: imprecision (serious, -1). The estimate of treatment effect relied largely on one study. It is unclear whether the estimate obtained from a small number of 
adverse reactions to a single dust mite extract in this study can be generalised. Indeed data from other populations suggest that specific allergen immunotherapy is generally 
associated with a small but significant risk of systemic adverse reactions. 
e. Reason for downgrading: study limitations (serious, -2), and imprecision (serious, -1). The estimate of treatment effect relied on two non-blinded studies. The information size is 
small. 
f. Reason for downgrading: study limitations (serious, -2), and imprecision (serious, -1). Two studies were non-blinded. Moderate proportions of participants were not analysed (losses 
to follow up). The information size is small. 
 
 
 27 
Table 3 Limitation of meta-analyses 
Limitation Details Implication for Future Studies 
Small studies N<100 for 10/12 studies Larger enrolment 
Heterogeneous outcomes Variability in reported outcomes in included studies Evaluate patient-reported primary outcomes 
Risk of bias Open-label studies 
High loss to follow-up 
Funding from manufacturer 
Double-blinded, randomized controlled trials 
Stringent methodology 
A priori protocol 
Subgroup analyses Insufficient evidence to assess differences between 
subgroups 
Larger trials with standard subgroup stratification to enable 
meta-analyses 
Assess clinically relevant allergy Included patients with allergen sensitization but not 
challenge-proven AE exacerbations 
Establishing challenge-proven exacerbation such as using a 
challenge chamber 
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Figure Legends 
Figure 1. PRISMA flow diagram. AE, atopic eczema; RCTs, randomised controlled trials; SIT, specific allergen 
immunotherapy 
Figure 2. Risk of bias in included studies. The Cochrane Risk of Bias tool was used to assess risk of bias in included 
studies. Green represents low risk, yellow unclear risk, red high risk of bias. 
Figure 3. Forest plots of participant- or parent-reported specific symptoms of eczema 
 
Figure 4. Meta-analyses of adverse events 
 
Figure 5. Meta-analyses of investigator- or physician-rated global disease severity 
 
Figure 6. Meta-analyses of investigator rated eczema severity using a published scale 
